Document:

<PAGE>
                                                                   Exhibit 10.46

                                [LOGO ENTREMED]

                             CONFIDENTIAL AGREEMENT
                               AND MUTUAL RELEASE

This Confidential Separation Agreement and General Release ("Agreement") is
entered into September 18, 2002 (the Effective Date) between EntreMed, Inc, a
Delaware corporation ("The Company") and Edward R. Gubish, Ph.D. ("you"). The
purpose of this Agreement is to set out the terms and conditions surrounding
your termination of employment from the Company.

1.   This is to confirm that your employment with the Company will cease,
     effective October 15, 2002 ("the termination date").

2.   The Company agrees to pay you, as severance, twelve (12) months of salary.
     You will receive separation payments of your regular salary less
     appropriate withholdings. These payments will be sent to you by mail or
     will be paid to you via direct deposit, if you so choose, on the Company's
     normal paydays for employees through October 15, 2003. You are not
     entitled to receive any additional compensation and you will not accrue
     additional separation or other pay during your inactive employment. In the
     event you commence employment elsewhere you will receive a lump sum
     corresponding to the portion of your salary payments that would have been
     paid out to you.

3.   Vacation accrual will cease on October 15, 2002. Under the Company's
     vacation policy you will receive a lump sum payment for any accrued and
     unused vacation days less appropriate withholding, on the normal payday
     after your active employment ends.

4.   You will receive stock option grants and/or bonuses for 2001, should they
     be granted by the EntreMed Board of Directors. You will receive stock
     option grants and/or bonuses for 2002, should they be granted by the
     EntreMed Board of Directors. The number of stock options granted to you for
     2002 is 40,000 options. All granted options that are unvested will be
     vested on the Effective Date of this agreement. You will be able to
     exercise any vested option held by you after leaving the Company through
     the original expiration date of the option (generally, 10 years from the
     original grant date). Your current options (including those granted in
     2002) total 672,001 and are listed on the attached schedule.
<PAGE>
5.   The Company shall have no other financial obligations to you under any
     compensation or benefit plan, program or policy, and your participation in
     the Company compensation and benefit plans, programs and policies shall
     cease as of the date of your termination, except that you shall have such
     right to continued group health plan coverage as is provided under COBRA.
     COBRA payments will be paid for 12 months after your termination date of
     October 15, 2002 or until you acquire a new position with a new employer.

6.   In exchange for the consideration described in this document, you agree to
     release and forever discharge the Company, its subsidiaries and affiliates
     and their parent organizations, predecessors, successors, officers,
     directors, employees, agents, attorneys, associates and employee benefit
     plans from all claims, demands or causes of action arising out of facts or
     occurrences prior to the date of this Agreement, whether known or unknown
     to you.

     The Company, for itself, its officers, directors, employees, agents and
     successors and assigns releases and forever discharges you and your heirs,
     successors and assigns from all claims, demands or causes of action arising
     out of facts or occurrences prior to the date of this Agreement, whether
     known or unknown, except to the extent that any such claim, demand or cause
     of action is based on your actions which do not meet the required standard
     for indemnification set forth in the Delaware Corporation Law (whether such
     actions were taken in your capacity as an officer or employee). In this
     connection it is understood that you shall be entitled to reimbursement
     applicable to your action or inactions as an officer or employee of the
     Company under the terms of the current Directors and Officers Liability
     Insurance and the Company will indemnify you in this regard to the extent
     provided by its By-Laws consistent with Delaware Law.

7.   You and the Company agree that the release of claims set forth herein is
     intended to be broadly construed so as to resolve any pending and potential
     disputes between you and the Company that may exist up to the date of such
     Release, whether or not such disputes are known or unknown, including, but
     not limited to, claims based on express or implied contract; any action
     arising in tort, including, but not limited to libel, slander, defamation,
     intentional infliction of emotional distress, or negligence; any or all
     claims for wrongful discharge; and any and all claims based on the Age
     Discrimination in Employment Act (42 U.S.C. section 621), Title VII of the
     Civil Rights Act of 1964 as amended (42 U.S.C. section 2000e), the Civil
     Rights Acts of 1866 and 1871 (42 U.S.C. section 1981), the Employee
     Retirement Income Security Act (29 U.S.C. section 1001), the Family and
     Medical Leave Act (29 U.S.C. section 2601), the Americans with Disabilities
     Act (42 U.S.C. section 12,101), the Occupational Safety and Health Act
     (29 U.S.C. section 651), the Maryland Fair Employment Practices Act, and
     any other applicable federal, state or local law, regulation, ordinance, or
     order.

                                     - 2 -
<PAGE>
     Notwithstanding anything to the contrary in this paragraph or in paragraph
     9, nothing in these paragraphs shall release or be construed to as
     releasing any claim, demand or cause of action arising under this
     Agreement.

8.   In further consideration for the compensation and benefits herein, you
     agree strictly to maintain the confidentiality of this Agreement and not to
     disclose its existence or its terms to anyone other than your spouse,
     attorney and any tax advisors except as may be required by law or legal
     process. The Company will similarly maintain the confidentiality of this
     Agreement and not disclose its existence or its terms to anyone other than
     to its professional advisors, to employee or agents who have a need to know
     and as may be required by law or legal process.

9.   In connection with litigation or proceedings or anticipated proceedings,
     before a court, arbitrator, administrative agency or other tribunal, should
     you be asked by the Company to testify as a witness or to provide
     information to the Company's counsel concerning matters you were involved
     in during the course of your employment with the Company, you agree to
     cooperate fully with the Company's counsel. You agree to make yourself
     available to such counsel to discuss your information and to review your
     testimony reasonably in advance of such litigation or proceedings and to
     make yourself available to testify at depositions or trial as required or
     requested by the Company. You will be reimbursed for travel expenses and
     statutorily-mandated witness fees; however, you agree that you will not be
     paid in connection with your testimony, appearance or participation
     pursuant to this paragraph in such litigation or proceedings.
     Notwithstanding the foregoing, in the event your appearance or testimony
     causes you a loss of regular employment earnings for said appearance or
     testimony, the Company will reimburse you for such loss of earnings.

10.  This Agreement is specifically conditioned on your continuing to abide by
     all the terms and conditions of this Agreement and the terms and conditions
     set forth in the Company's standard confidentiality agreement, including,
     but not limited to, your agreement not to disclose any information to any
     third party relating to the Company's research, finances, product
     development, manufacturing, business/commercial development, sales and
     marketing strategies and activities. You agree not to make any false,
     disparaging or derogatory statements in public or private regarding the
     Company or any of its officers, directors, employees, agents or
     representatives or the Company's business affairs or financial condition.
     The Company agrees that neither it nor any of its officers, directors or
     agents will make any false, disparaging or derogatory statements in public
     or private in connection with or concerning your service to the Company or
     your separation therefrom. In addition, in regard to any inquiries made by
     third parties with respect to your employment

                                     - 3 -
<PAGE>
     at the Company, the Company will confirm only your dates of employment, job
     title and salary and you and the Company shall mutually agree upon any
     public statements regarding your separation from the Company before its
     issuance. Further, for a period of nine (9) months after termination of
     your active employment with the Company, you agree not to, as an
     individual, principal, agent, employee, consultant or otherwise, directly
     or indirectly in the United States render any services to Celgene
     Corporation.

11.  Moreover, for a period of nine (9) months after the termination of your
     employment (October 15, 2002) with the Company, you agree not to take any
     action to assist your successor employer or any other entity in recruiting
     or hiring any other employee who had worked for the Company during any of
     the time period when you worked for the Company. This includes (a)
     identifying to such successor employer or its agents or such other entity,
     the person or persons who have special knowledge concerning the Company's
     inventions, processes, methods or confidential affairs; or (b) commenting
     to your successor employer or its agents or such other entity about the
     quantity of work, quality of work, special knowledge or personal
     characteristics of any person who is still employed at the Company. You
     also agree that you will not provide such information to a prospective
     employer during interviews preceding possible employment. If you breach or
     challenge the enforceability of this Agreement in a court of law before an
     administrative agency, you acknowledge that you will reimburse the Company
     for any monetary consideration previously received by you under this
     Agreement. If the Company breaches this Agreement, the Company acknowledges
     that it may be liable for monetary damages you incurred as a result and/or
     you may be entitled to equitable relief. You and the Company agree that the
     prevailing party in any proceeding (judicial or administrative) to enforce
     this Agreement will be entitled to an award of reasonable attorneys' fees
     and costs actually incurred.

12.  You expressly agree that you will not apply for reinstatement or
     reemployment with the Company, although this obligation will not be
     applicable to any entity which may acquire all of the assets of the Company
     or be the surviving entity following a merger with the Company.

13.  You shall immediately return to the Company all notes, reports, plans,
     keys, security cards and/or identification cards, customer lists, product
     information and other documents and property that were created, developed,
     generated or received by you during your employment or that are the
     property of the Company, whether or not such items are confidential to the
     Company. It is understood that this obligation does not apply to items that
     are clearly intended to be retained by you after separation from the
     Company, i.e., pay stubs. It is also understood that this obligation does
     not apply to your laptop computer.

                                      -4-
<PAGE>
14.  This agreement shall not be construed as an admission by the Company of
     any wrongdoing or any violation of federal, state or local law, and the
     Company specifically disclaims any wrongdoing against, or liability to you.

Ed Gubish acknowledges and agrees as follows:

15.  I have read and understand this Agreement in its entirety;

     a.   I have been advised by the Company to consult with an attorney before
          signing this Agreement and this paragraph constitutes such advice in
          writing;

     b.   I have been advised that I have 45 days from the date of this
          agreement to sign and return the agreement to EntreMed, Inc. in order
          for this agreement to take effect. I also understand that I have
          7 days from the date of signature to revoke the signed agreement; and

     c.   I have entered this Agreement knowingly and voluntarily, without
          duress or reservation of any kind, and after having given the matter
          full and careful consideration.

16.  This Agreement contains the entire agreement between you and the Company
     concerning your separation from employment.

17.  This Agreement shall be construed and enforced under Maryland law without
     regard to conflict of law principles, to the extent not governed by
     federal law.

18.  In the event any portion of this Agreement is deemed to be invalid or
     unenforceable, that portion will be deemed to be omitted and the remainder
     of this Agreement will remain in full force and effect.

            PLEASE READ CAREFULLY. THIS AGREEMENT INCLUDES A RELEASE
                    OF ALL CLAIMS, WHETHER KNOWN OR UNKNOWN,
                YOU MAY HAVE IN CONNECTION WITH YOUR EMPLOYMENT
                                WITH THE COMPANY.

Dated: September 18, 2002

                                                    /s/ Edward R. Gubish, Ph.D.
                                                    ----------------------------
                                                        Edward R. Gubish, Ph.D.

/s/ John W. Holaday
--------------------------
By: John W. Holaday
Chairman and CEO
EntreMed, Inc.

                                     - 5 -<PAGE>
                                                                   Exhibit 10.47

                              TRANSITION AGREEMENT

This Transition Agreement ("Agreement") is entered into between EntreMed, Inc.,
a Delaware corporation, (the "Company") and Dr. John W. Holaday ("Dr. Holaday").
The purposes of this Agreement are to set out the terms and conditions
surrounding Dr. Holaday's orderly and amicable transition from the Company as an
employee, officer, Director and as the Chairman of the Board of Directors of the
Company (the "Board") and as the Company's representative on the Board of
Directors of MaxCyte, Inc., and to confirm that Dr. Holaday hereby submits or
has previously submitted his resignation from all such positions effective as
indicated below.

                                   BACKGROUND

A.   The parties recognize the leadership role of Dr. Holaday as one of the
     founders and largest shareholders of the Company, having served as its
     Chief Executive Officer since its inception until October 31, 2002, and
     having served as its Chairman of the Board (the "Chairman") from 1995 until
     January 31, 2003 consistent with Dr. Holaday's tender of his resignation
     from such position as Chairman and as a Director and member of the Board to
     be effective January 31, 2003.

B.   The leadership role of Dr. Holaday in connection with a critically
     important transaction between the Company and Celgene in 2002 is recognized
     and appreciated.

C.   Effective as of November 5, 2002, Dr. Holaday stepped down as Chief
     Executive Officer of the Company.

D.   Dr. Holaday agreed to assist the Company as it repositions itself in the
     marketplace by serving as Chief Scientific Officer of the Company and in
     this capacity to assist in the refocus of its Scientific programs, to work
     to maintain morale, and to retain key employees from November 5, 2002,
     until January 31, 2003.

E.   Dr. Holaday and the Company are parties to an Employment Agreement entered
     into on or about January 1, 1999, (the "Employment Agreement"), pursuant to
     which, among other things, the Company was obligated, under certain
     circumstances, to pay to him the full amount of his Base Salary, as defined
     in such Employment Agreement, through December 31, 2003.

F.   For personal reasons, Dr. Holaday has decided to resign as Chief Scientific
     Officer of the Company and to resign his position as a Director and member
     of the Board, including his position as Chairman of the Board, and his
     position as the Company's representative on the Board of Directors of
     MaxCyte, Inc.

G.   The Company recognizes contributions made by Dr. Holaday over years of
     service and desires to be able to call upon him for consultation, advice
     and assistance (without additional compensation), through the Board,
     including particularly any future Chairman, senior Company executives and
     the Company's counsel, from time to time, particularly during calendar year
     2003 but possibly thereafter, and the parties to this Agreement further
     agree as follows:

EntreMed, Inc. [Signature]                                     JWH [Signature]
<PAGE>
                                   AGREEMENT

1.   Effective as of November 5, 2002, Dr. Holaday stepped down as Chief
     Executive Officer of the Company.

2.   Effective as of November 5, 2002, Dr. Holaday began service as Chief
     Scientific Officer of the Company at the salary of Three Hundred
     Thirty-Three Thousand Nine Hundred and No/100 Dollars ($333,900.00) if it
     were paid over an annual period, with such duties in connection therewith
     as have been or shall reasonably be assigned to Dr. Holaday by the Board or
     its designee from November 5, 2002, until January 31, 2003, the latter date
     being the "Termination Date" of Dr. Holaday's employment by the Company.
     The term of Dr. Holaday's employment as the Company's Chief Scientific
     Officer and in any employment capacity whatsoever shall end on January 31,
     2003. The decision of Dr. Holaday to terminate any employment by the
     Company as of and no later than January 31, 2003, is irrevocable, and the
     Company has relied on this decision of Dr. Holaday to terminate such
     employment. Dr. Holaday agrees that he shall not represent himself as an
     employee or officer of the Company at any time after January 31, 2003. Dr.
     Holaday expressly promises that he has not undertaken or made any
     financial, legal or other obligation on behalf of the Company that has not
     been fully disclosed to and approved by the Board except for small
     reasonable, ordinary and necessary business expenses incurred on behalf of
     the Company, and the Company relies upon this promise. Dr. Holaday
     expressly promises that since January 16, 2003, and continuing to and
     through January 31, 2003, he has not undertaken or made and shall not
     undertake or make any financial, legal or other obligations on behalf of
     the Company that in the aggregate exceed Five Hundred Dollars ($500.00) in
     costs or effect upon the Company. Consistently with the foregoing, the
     Company agrees to reimburse Dr. Holaday for reasonable, ordinary and
     necessary business expenses, properly supported by appropriate records and
     in accordance with Company policies, incurred by Dr. Holaday on behalf of
     the Company through January 16, 2003, and for such reasonable, ordinary and
     necessary business expenses, properly supported by appropriate records and
     in accordance with Company policies, incurred by Dr. Holaday between
     January 17, 2003, and January 31, 2003, so long as all such expenses
     exceeding Five Hundred Dollars ($500.00) in the aggregate have been or were
     approved in advance of incurring them by a duly authorized representative
     of the Board other than Dr. Holaday. Further, Dr. Holaday also hereby
     resigns as a Director and member of the Board and as its Chairman and as
     the representative of the Company on the Board of Directors of MaxCyte,
     Inc., effective as of the close of business on January 31, 2003. Dr.
     Holaday agreed that he shall not represent himself as a Director and member
     of the Board or as its Chairman or as the Company's representative on the
     Board of Directors of MaxCyte, Inc., at any time after January 31, 2003.
     During Dr. Holaday's term of employment as Chief Scientific Officer of the
     Company, he has been and will be entitled to participate in group medical
     and life insurance plans sponsored by the Company. In addition, The
     Hartford Life Insurance Company life insurance policy on the lives of Dr.
     Holaday and Dorinda A. Holaday (Policy date: 02/26/96, number:
     LL6025052-13) ("the Policy") currently in place as of January 1, 2003, will
     be maintained through and until the Termination Date of Dr. Holaday's
     employment, and the premium for the Policy for the annual period beginning

EntreMed, Inc. [Signature]              -2-                    JWH [Signature]

<PAGE>
     February 26, 2003. will be paid by the Company upon timely presentation of
     the annual Policy premium notice. Any and all rights to the repayment of
     premiums ("Premium Repayment") paid by the Company for the Policy out of
     death benefits under the Policy or otherwise shall be relinquished and
     waived by the Company at the time the payments by the Company to Dr.
     Holaday that will be made pursuant to Paragraph 3 below are made. To the
     extent any obligation from the Company toward Dr. Holaday personally may
     have been created by either an agreement entitled "Split Dollar Insurance
     Agreement" entered into effective the 27th day of March, 1996, by and
     between EntreMed, Inc. (therein called "Employer"), and the Holaday Family
     Trust No. 2 U/A DTD 11/15/95, James D. Johnson, Trustee (therein called
     "Split Dollar Insurance Agreement") or by an assignment contract related
     thereto that is entitled "Collateral Assignment" made and entered into
     effective the 27th day of March, 1996, by EntreMed, Inc., (therein called
     the "Assignee") and James D. Johnson, Trustee, Holaday Family Trust No. 2
     U/A DTD 11/15/95, Owner, with respect to the Policy, and any supplementary
     contracts issued in connection therewith (said policy and contracts being
     therein called the "Policy"), upon the life of John W. Holaday (referenced
     therein as "Holaday") and Dorinda B. Holaday, to EntreMed, Inc., a Delaware
     corporation, all such rights are extinguished, canceled and terminated as
     of the date this Agreement becomes effective and enforceable pursuant to
     Paragraph 34(b) below, and it is agreed that the Company shall have no
     additional obligation with respect thereto except as expressly specified in
     this Agreement.

3.   On or before the later of (a) Dr. Holaday's Termination Date or (b) ten
     (10) business days after this Agreement becomes effective and enforceable
     in accordance with Paragraph 34(b) below, the Company agrees to pay
     Dr. Holaday, by check, as severance, the sum of Fifty-Five Thousand Six
     Hundred Fifty and No/100 Dollars ($55,650.00) ("Severance"), and a lump sum
     in the amount of Fifty Thousand Five Hundred Thirteen  and 44/100 Dollars
     ($50,513.44) representing payment in lieu of paid time off for twenty-nine
     and one-half (29.5) accrued but unused Paid Time Off ("PTO") days, both
     amounts less applicable withholdings for taxes, FICA and Medicare payments
     for the Severance, the PTO, the waiver by the Company of the Policy Premium
     Repayment obligation, any other services or benefits provided to
     Dr. Holaday that are subject to such a withholding obligation, and the
     value of the laptop computer that Dr. Holaday has used during employment
     with the Company until January 31, 2003, that will be provided to Dr.
     Holaday pursuant to this Agreement if it becomes effective and enforceable
     pursuant to Paragraph 34(b) below. Dr. Holaday will be entitled to receive
     the Severance payment, less applicable withholdings, provided for in this
     Paragraph whether or not Dr. Holaday has other employment after his
     Termination Date.

4.   Paid time off ("PTO") accrual will cease on the Termination Date. Except as
     expressly provided for in this Agreement, Dr. Holaday shall not accrue any
     compensation, benefits from or sponsored by the Company or any other
     emoluments associated with employment after the Termination Date.
     Dr. Holaday shall not accrue any compensation, benefits from or sponsored
     by the Company or any other emoluments associated with service to the
     Company as Chairman or such service as a Director and member of the Board
     or its representative on the Board of MaxCyte, Inc., after January 31,
     2003.

EntreMed, Inc. [Signature]              -3-                    JWH [Signature]
<PAGE>
     Without limitation, effective by the close of business January 31, 2003,
     Dr. Holaday must have canceled all cellular telephone services, electronic
     messaging services, and all other such contracts for services currently
     paid for by the Company and entered into new contracts for which he
     personally is financially responsible if he wishes such services. Dr.
     Holaday may access his Company telephone until February 28, 2003. He agrees
     that he will forward any telephone message that pertains to the Company's
     business or potential business or that is of potential interest to the
     Company to Margot Mongold at her Company telephone number as specified in
     Paragraph 23 below. Without limiting the provisions of Paragraph 22 below,
     Dr. Holaday may access and send e-mail from his EntreMed, Inc., e-mail
     address until February 28, 2003. Dr. Holaday agrees that as an additional
     safeguard to the Company with respect to its business, potential business
     and matters of interest to it, he will forward all such incoming and
     outgoing e-mails to Ms. Mongold if she has not been a recipient of such
     original incoming or outgoing e-mail message. While the Company shall not
     pay for Dr. Holaday's consultation with media consultants or consulting
     groups, Dr. Holaday may use any such person or group as his personal
     consultants and personally pay for such services.

5.   All stock options granted to Dr. Holaday on or before January 1, 2003, that
     are unvested as of the Termination Date will be vested in Dr. Holaday on
     the date this Agreement becomes effective and enforceable pursuant to
     Paragraph 34(b) below of this Agreement. Dr. Holaday will be able to
     exercise any such vested option held by Dr. Holaday through the original
     expiration date of the option (generally, ten (10) years from the original
     grant date). Dr. Holaday's options, which total 1,436,669, are listed on
     the attached Schedule A. The Company shall promptly issue to Dr. Holaday a
     warrant to purchase up to One Hundred Thousand (100,000) shares of common
     stock if this Agreement becomes effective and enforceable in accordance
     with Paragraph 34(b) below. The warrant will be exercisable in
     non-cumulative monthly installments for Ten Thousand (10,000) shares of
     common stock ("Monthly Allotment"), beginning on the date that this
     Agreement becomes effective and enforceable in accordance with Paragraph
     34(b) below and, thereafter, on the first day of the next nine (9) months
     for a total of ten (10) months. To the extent that the Monthly Allotment is
     not exercised on or before the close of business on the last business day
     in any given month, the warrant shall expire with respect to such Monthly
     Allotment. The warrant will be exercisable, in cash, at a price per share
     equal to the closing price per share on January 29, 2003. Dr. Holaday
     understands and acknowledges that the warrant and the Monthly allotment, if
     any, will be issued in reliance on exemptions from registration under the
     Securities Act of 1933, as amended, and state securities laws. Dr. Holaday
     further understands that neither the warrant nor the Monthly Allotment may
     be sold or transferred other than in reliance on an exemption from
     registration or qualification under federal and state securities laws.
     Details concerning the terms of the warrant shall be governed by the
     warrant which shall contain such details consistent with this description
     and applicable laws and regulations as have been customary in the Company's
     other similar warrants. In addition to all other options available under
     Paragraph 24 below, if the grant of this warrant or the exercise of any
     Monthly Allotment creates a withholding obligation with respect to taxes,
     FICA and Medicare payments, Dr. Holaday shall tender a check to the Company
     for all such taxes,

EntreMed, Inc. [Signature]                                       JWH [Signature]
                                      -4-
<PAGE>
     FICA and Medicare payments by the fifth (5th) day or next business day
     thereafter after such obligation to make such payments to the government
     has been created.

6.   Beginning on the later of (a) February 15, 2003, or (b) ten (10) business
     days after this Agreement becomes effective and enforceable pursuant to
     Paragraph 34(b) below, on the fifteenth (15th) day and on the last day of
     each month beginning in February, 2003, and ending on January 31, 2004,
     the Company will pay Dr. Holaday, by check or by direct deposit if that is
     administratively reasonable under procedures with ADP and preferred by Dr.
     Holaday, the sum of Twenty Thousand Four Hundred Five and No/100 Dollars
     ($20,405.00), less applicable withholdings for taxes, FICA and Medicare
     payments for such payments and for any other benefit provided to
     Dr. Holaday that is subject to such withholdings if this Agreement becomes
     effective and enforceable pursuant to Paragraph 34(b) below, whether or
     not Dr. Holaday has other employment after his Termination Date.

7.   Provided that (a) Dr. Holaday properly completes necessary coverage
     continuation documents and elects continued coverage under the Consolidated
     Omnibus Budget Reconciliation Act ("COBRA") for health care insurance under
     a Unicare/NCPPO policy (medical and dental) after his Termination Date for
     himself and his dependents covered by such insurance as of January 31,
     2003, (b) Dr. Holaday remains eligible for such coverage, and (c) this
     Agreement becomes effective and enforceable in accordance with Paragraph
     34(b) below, the Company will pay the COBRA premium for such health care
     insurance coverage (or for such other health care insurance, if any, as
     may then be made available to senior executives of the Company) through
     and including January 31, 2004, after which time Dr. Holaday may make
     timely premium payments in accordance with the provisions of COBRA and
     applicable Company procedures if Dr. Holaday and his covered dependents
     remain otherwise eligible for such coverage.

8.   The Company agrees to reimburse Dr. Holaday for his reasonable fees and
     related expenses for executive outplacement services, including for travel
     to confer with such consultants and the like, that are incurred on or
     before January 31, 2004, in an amount up to Ten Thousand and No/100
     Dollars ($10,000.00), less withholdings for taxes, FICA and Medicare
     payments. Dr. Holaday may not elect to receive cash in lieu of
     reimbursement for such incurred outplacement services and related expenses.

9.   In exchange for the consideration described in this Agreement, Dr. Holaday
     hereby voluntarily and irrevocably releases and forever discharges the
     Company, its subsidiaries and affiliates (including without limitation
     Cytimmune, Inc., MaxCyte, Inc., and Celgene Corp.) and all of their
     respective parent companies and organizations, predecessors and successors
     and all of their respective officers, directors, employees, agents,
     attorneys, associates and employee benefit plans from all claims and
     obligations arising out of facts injuries, incidents, circumstances and
     occurrences, whether known or unknown to him, occurring from the beginning
     of time until the date and time Dr. Holaday executes this Agreement,
     including, without limitation, any and all claims and obligations arising
     out of Dr. Holaday's employment with the Company, including terms and
     conditions of such employment, and the termination of such employment as
     of January 31, 2003,

EntreMed, Inc. [SIGNATURE]              - 5 -                    JWH [SIGNATURE]

<PAGE>
     (specifically including, but not limited to, any and all claims under the
     Civil Rights Acts of 1866, 1871, 1964 (including Title VII of such Act) and
     1991, the Rehabilitation Act of 1973, the Age Discrimination in Employment
     Act of 1967 ("ADEA"), the Older Workers Benefit Protection Act of 1990
     ("OWBPA"), the Americans with Disabilities Act of 1990, the Employee
     Retirement Income Security Act of 1974 (except as to any benefits that are
     vested as of the Termination Date), the Family and Medical Leave Act of
     1993, the Immigration Reform and Control Act of 1986, the Worker Adjustment
     and Retraining Notification Act of 1988, the Maryland Fair Employment
     Practices Act, and under all regulations issued under all of these statutes
     and all amendments to all of them whether expressly referenced or not, and,
     including, without limitation, any and all claims for severance pay, based
     on alleged express or implied contract except for claims for breach of this
     Agreement, claims for wrongful discharge and for intentional or negligent
     infliction of emotional distress), any action arising in tort, including,
     but not limited to, libel, slander, defamation and negligence, any claim
     for costs or attorneys' fees incurred by Dr. Holaday in connection with the
     drafting and negotiation of this Agreement and any claim or obligation
     under any law, constitution or regulation, ordinance or order or under any
     common law or equitable theory of recovery or relief. The word "claim(s)"
     in this Paragraph refers to and includes all claims, demands, disputes,
     rights, suits, charges, complaints, causes, proceedings, actions, rights of
     action, causes of action, rights of subrogation, rights of indemnity,
     rights to reimbursement, rights to payment, liens and remedies of every
     kind or nature whatsoever, whether the same are or any of the same is at
     law, in equity or otherwise, and whether the same are or any of the same is
     known or unknown, foreseen or unforeseen, suspected or unsuspected, and
     whether or not concealed or hidden. The word "obligation(s)" in this
     Paragraph refers to and includes all obligations, duties, liabilities,
     agreements, promises, illnesses, injuries, damages, costs, fees (including,
     without limitation, attorneys' fees), losses, expenses and debts of every
     kind or nature whatsoever, whether the same are or any of the same is at
     law, in equity or otherwise, and whether the same are or any of the same is
     known or unknown, foreseen or unforeseen, suspected or unsuspected, and
     whether or not concealed or hidden. The phrase "arising out of" in this
     Paragraph and in Paragraph 10 means directly or indirectly resulting from,
     connected with or in any matter related to, in the past, present or future,
     the subject to which the phrase refers. NOTWITHSTANDING any other provision
     of this Agreement, Dr. Holaday does retain the rights to file a charge of
     discrimination under the ADEA, to contest the validity of this Agreement
     under the provisions of the OWBPA and to take other permissible action
     should it be held invalid, and to participate in an investigation or
     proceeding under the ADEA or the OWBPA conducted by the EEOC, but Dr.
     Holaday does waive any right to seek, recover or accept any monetary
     damages, back pay or any other remedy from the Company or from any other
     party released by the provisions of this Paragraph resulting from any
     investigation or legal action by the EEOC or by any other person or entity
     with respect to any claim or charge of age discrimination under the ADEA
     unless this Agreement is held invalid under the ADEA and the OWBPA.

10.  The Company releases and discharges Dr. Holaday and his heirs, successors
     and assigns from all claims, demands or causes of action arising out of
     facts or occurrences prior to the Termination Date, whether known or
     unknown except to the extent that any such

EntreMed, Inc. [Signature]                                      JWH [Signature]

                                     - 6 -
<PAGE>
     claim, demand or cause of action is based on Dr. Holaday's actions or
     inactions (a) that do not meet the required standard for indemnification
     set forth in the Delaware Corporation Law or applicable By-Laws of the
     Company, (b) except to the extent that any such claim, demand or cause of
     action is based on Dr. Holaday's actions or inactions that were not
     disclosed to the Board of Directors of the Company (whether such actions or
     inactions were taken in Dr. Holaday's capacity as an officer, director, or
     employee), and (c) except to the extent that is would not be permissible
     under applicable standards for the Company to release claims and
     obligations arising out of any such acts and omissions. The Company shall
     use commercially reasonable efforts to maintain for a period of not fewer
     than three (3) years after the date this Agreement becomes effective and
     enforceable pursuant to Paragraph 34(b) below, directors and officers
     liability insurance covering Dr. Holaday's actions and inactions as a
     former officer, Director and member of the Board and former Chairman of the
     Board and former representative of the Company on the Board of MaxCyte,
     Inc., to the same extent afforded the Company's then current and other
     former officers. The Company will indemnify Dr. Holaday for all such
     actions and inactions to the extent provided for any other similarly
     situated current or former officer of the Company and consistently with the
     Company's current By-Laws and applicable provisions of Delaware Law.

11.  Notwithstanding anything suggesting to the contrary in Paragraphs 9 or 10
     above, nothing in this Agreement shall release or be construed to as
     releasing any claim, demand or cause of action for breach of this
     Agreement.

12.  In connection with business operations of the Company and actual or
     potential litigation, the Company desires that the Board, individual Board
     members, including a future Chairman, senior executives of the Company, and
     the Company's counsel ("Authorized Company Representatives") have
     opportunities to avail themselves of the consultations, assistance and
     advice that Dr. Holaday may be able to provide them and in connection with
     litigation or proceedings or anticipated proceedings before a court,
     arbitrator, administrative agency or other tribunal. Should Dr. Holaday be
     asked by Authorized Company Representatives to provide consultations,
     advice and assistance to the Company through them or to testify as a
     witness or to provide information to the Company's counsel concerning
     matters in which Dr. Holaday was involved during the course of his
     employment with the Company as an employee or officer or during his tenure
     as Chairman and as a Director and member of the Board or during his tenure
     as the Company's representative on the Board of Directors of MaxCyte, Inc.,
     Dr. Holaday agrees to cooperate fully with such Authorized Company
     Representatives, including the Company's Chairman and the Company's
     counsel. Dr. Holaday agrees to make himself reasonably available to such
     Authorized Company Representatives, including the Company's counsel for
     consultations, advice, assistance and discussions. Dr. Holaday agrees to
     make himself available to the Company's counsel to discuss information and
     to review his testimony reasonably in advance of such litigation or
     proceedings and to make himself available to testify at depositions or
     trial as required or requested by the Company. Dr. Holaday will be
     reimbursed for travel expenses and statutorily mandated witness fees;
     however, Dr. Holaday agrees that he will not be paid in connection with his
     consultations, advice, assistance, testimony, appearances or his
     participations pursuant to

EntreMed, Inc. [Signature]                                      JWH [Signature]

                                      -7-
<PAGE>
     this Paragraph in such litigation or proceedings. Notwithstanding the
     foregoing sentence, in the event Dr. Holaday's consultations, advice,
     assistance, appearances or testimony at the specific request of the Company
     cause him, after January 31, 2004, to spend more than 100 hours in the
     aggregate (a) preparing for and providing such consultations, advice,
     assistance and discussions and (b) making any such appearances or giving
     any such testimony and the Company's Chairman or the Company's counsel has
     authorized and requested that Dr. Holaday spend additional time in
     preparing for and providing such consultations, advice, assistance,
     discussions, appearances, in making such appearances or in giving
     testimony, the Company will reimburse Dr. Holaday at the rate of $100 per
     hour for all time in addition to such 100 hours spent by Dr. Holaday in
     connection with such requests by the Company's Chairman or the Company's
     counsel. In the event that Dr. Holaday receives a subpoena or other legal
     process seeking his appearance, testimony, documents or other information
     related to the Company or to any third person released in Paragraph 9
     above, Dr. Holaday shall immediately, and in no event later than
     forty-eight (48) hours after the receipt, give written notice to the
     Company through the person specified in Paragraph 23 below, of his receipt
     of such subpoena or other legal process by facsimile and by overnight,
     next-day courier delivery, the cost of which will be paid by the Company.
     Dr. Holaday agrees that he shall not appear or release any such information
     in response to a subpoena or other legal process without first allowing the
     Company a reasonable opportunity to challenge and seek to quash such
     subpoena or legal process through court proceedings if it elects to do so.

13.  This Agreement is specifically conditioned on Dr. Holaday having abided by
     and continuing to abide by all the terms and conditions of this Agreement
     and the terms and conditions set forth in the Company's Combined
     Non-disclosure and Patent Employee Agreement that he previously executed,
     including, but not limited to, Dr. Holaday's agreement not to disclose any
     information to any third party relating to the Company's research,
     finances, product developments, manufacturing, business/commercial
     development, sales and marketing strategies and activities. The Company
     agrees that no officer or director of the Company, acting on behalf of the
     Company, shall make any public false, disparaging or derogatory statements
     in connection with or concerning Dr. Holaday's service to the Company
     except as may be required for truthful, sworn testimony or in connection
     with a legal or administrative case, proceeding, report, claim or dispute.
     Dr. Holaday agrees that he shall not make any public false, disparaging or
     derogatory statements in connection with or concerning the Company or any
     officer or director of the Company except as may be required for truthful,
     sworn testimony or in connection with a legal or administrative case,
     proceeding, report, claim or dispute. The parties agree and understand that
     comments to the effect that "the Company is changing directions, is
     pursuing new avenues, the Company has different senior officers and
     directors, that the Company has made some mistakes in the past" and the
     like are not false, disparaging or derogatory remarks. In addition, Dr.
     Holaday shall direct all inquiries by third parties with respect to Dr.
     Holaday's employment at the Company to Margot Mongold, the Company's Senior
     Director of Human Resources, or her successor, and she or her successor
     will confirm only Dr. Holaday's dates of employment, job titles and last
     salary.

EntreMed, Inc. [Signature]                                       JWH [Signature]

                                      -8-
<PAGE>

14.  For a period of nine (9) months after his Termination Date, Dr. Holaday
     agrees not to take any action, without the prior written consent of the
     Company, to assist any successor employer of Dr. Holaday or any other
     entity in recruiting or hiring any other person who was an employee of the
     Company or who performed work for the Company as an independent contractor
     or in any other capacity during any time when Dr. Holaday was an employee
     of the Company. Examples of the types of actions Dr. Holaday agrees he
     shall not take include (a) identifying to any successor employer or its
     agents or any other entity the person or persons who have special knowledge
     concerning the Company's inventions, processes, methods or confidential
     affairs and (b) commenting to Dr. Holaday's successor employer or its
     agents or other entity about the quantity of work, quality of work, special
     knowledge or personal characteristics of any person who is still employed
     by the Company. Dr. Holaday also agrees that he shall not provide such
     information to a prospective employer during interviews preceding possible
     employment.

15.  If Dr. Holaday challenges the enforceability of this Agreement in a court
     of law or before an administrative agency, except as permitted under the
     ADEA and OWBPA as provided for in the last sentence of Paragraph 9 above,
     Dr. Holaday acknowledges that he shall reimburse the Company for all
     monetary consideration previously received by him under Paragraphs 3 and 6
     above. If the Company breaches this Agreement, the Company acknowledges
     that it may be liable for monetary damages Dr. Holaday incurs as a result
     and that he may be entitled to equitable relief. Dr. Holaday and the
     Company agree that the prevailing party in any proceeding (judicial or
     administrative) to enforce this Agreement shall be entitled to an award of
     reasonable attorneys' fees and costs actually incurred.

16.  Dr. Holaday expressly agrees that he shall not apply for and shall not be
     considered for reinstatement or reemployment as an employee of the Company,
     although this specific obligation shall not be applicable to any entity
     that may acquire all or part of the assets of the Company or be the
     surviving entity following a merger with the Company.

17.  On or before January 31, 2003, Dr. Holaday shall return to the Company
     through Margot Mongold, Senior Director Human Resources, or another
     designee of the Board all Company invention, research, business,
     production, and employee-related paper and electronic notes, files,
     reports, manuals, records and plans, computer software, credit cards, keys,
     building entry cards, security cards and Company identification cards,
     customer lists, product information and other documents and property that
     were created, developed, generated or received by Dr. Holaday during his
     employment with the Company or that are the property of the Company,
     whether or not such items are confidential to the Company and whether or
     not they were received from the Company or from an actual or potential
     business partner or investor of the Company, from a customer or vendor of
     the Company, or from any other source so long as they pertain to the
     Company ("Company Materials"). It is understood that this obligation does
     not apply to items that were and are clearly intended to be retained by Dr.
     Holaday after his separation from the Company, i.e., pay stubs. It is also
     understood that this obligation does not apply to Dr. Holaday's personal
     calendar and to his laptop computer, both of which, after removal of all
     Company Materials from them by Ms. Mongold or by a person designated

EntreMed, Inc. (signature)            -9-                       JWH (signature)
               -----------                                          -----------

<PAGE>
     by her, in accordance with regular Company policies and procedures, shall
     become Dr. Holaday's personal property after this Agreement becomes
     effective and enforceable pursuant to Paragraph 34(b) below. In addition,
     Dr. Holaday shall have the right to copy and retain a copy of specific
     Company Materials, the selection and retention of which by Dr. Holaday must
     be approved by a duly appointed representative of the Board other than Dr.
     Holaday before they are removed from the premises of the Company, and to
     the possession of items of artwork and other items that were purchased by
     Dr. Holaday and are his personal property as set forth in Schedule B
     attached hereto and made part of this Agreement. Dr. Holaday may make
     arrangements with Ms. Mongold for a mutually convenient date and time for
     the removal of Dr. Holaday's personal property from the Company's
     facilities. The Company shall pay for the removal and delivery of furniture
     owned by Dr. Holaday to his home at the address contained in Paragraph 22
     below; withholdings for taxes, FICA and Medicare applicable to such service
     will be withheld from any other funds otherwise due to Dr. Holaday, or at
     the Company's request, he shall promptly deliver a check to the Company to
     cover all such withholdings. The Company will make arrangements for the
     removal and delivery to the address in Paragraph 22 of Dr. Holaday's
     personal artworks (paintings, sculptures, etc.), but he shall be
     responsible for all costs, fees and expenses associated therewith,
     including any breakage and all risk of loss or damage to such items.
     Nothing in this Paragraph reduces or otherwise effects the obligations
     toward the Company that Dr. Holaday has undertaken in the Combined
     Non-disclosure and Patent Employee Agreement that he entered into in favor
     or the Company or the requirements of Paragraph 13 above. Further, Dr.
     Holaday acknowledges that trade secrets of the Company are worthy of
     protection and are the sole property of the Company and of the other
     entities from which and about which he has received such information. Dr.
     Holaday agrees that he will not personally or on behalf of any other person
     or entity divulge or make use of any trade secrets of the Company.

18.  In the event of Dr. Holaday's death at any time after his execution of
     this Agreement, his employment with the Company shall be deemed to have
     terminated as of the earlier of such date or January 31, 2003, and all
     payments and benefits described in this Agreement shall be paid or
     provided to Dr. Holaday's estate so long as this Agreement becomes
     effective and enforceable pursuant to Paragraph 34(b) below.

19.  This Agreement contains the entire agreement between Dr. Holaday and the
     Company concerning Dr. Holaday's separation from the employment of the
     Company and concerning the discontinuation of Dr. Holaday's service to the
     Company as Chairman of the Board and as a Director and member of the Board
     and as the Company's representative on the Board of Directors of MaxCyte,
     Inc. This Agreement shall not be modified except in writing, and all prior
     agreements except for the Combined Non-disclosure and Patent Employee
     Agreement entered into by and between Dr. Holaday and the Company, whether
     written or oral, including the Employment Agreement, relating to his
     employment by the Company shall be void and of no further force or effect
     beginning on the date this Agreement becomes effective and enforceable
     pursuant to Paragraph 34(b) below.

EntreMed, Inc. (signature)            -10-                       JWH (signature)
               -----------                                           -----------
<PAGE>
20.  This Agreement shall not be construed as an admission by Dr. Holaday or by
     the Company of any wrongdoing by Dr. Holaday or by the Company or by any
     person or entity released by the provisions of Paragraphs 9 and 10 above or
     of any violation of federal, state or local law at any time and for any
     purpose, and the Company and Dr. Holaday specifically disclaim any
     wrongdoing against or liability to the other.

21.  Two exact originals of this Agreement will be executed by Dr. Holaday and
     by the Company, and one original will be provided to the two respective
     parties upon full execution of both originals.

22.  Electronic and paper documents that are addressed or delivered to Dr.
     Holaday and that are received by the Company or at its business offices
     shall be opened to determine if they pertain to the Company's business or
     to Dr. Holaday personally; those that pertain to Dr. Holaday personally
     will be forwarded to him at 6502 Hillmead Road, Bethesda, Maryland 20877,
     Telephone: (301) 365-2803, and Telefax: (301) 365-8054, and all written
     notices to be provided to Dr. Holaday under this Agreement will be
     delivered to that address unless and until Dr. Holaday provides notice of a
     different address to the Company.

23.  Any notice or communication to the Company from Dr. Holaday that is
     required or permitted under this Agreement for which no specific recipient
     of the notice or communication procedure is provided in the Agreement shall
     be provided in writing and shall be delivered (a) personally, (b) by
     certified or registered U.S. mail postage prepaid and return receipt
     requested or (c) by overnight private courier or U.S. mail requiring
     written notice and confirmation of receipt, all addressed as follows:

          Attn: Ms. Margot Mongold
          Senior Director, Human Resources
          EntreMed, Inc.
          9640 Medical Center Drive
          Rockville, Maryland 20850
          Telephone: (240) 864-2630
          Telefax: (301) 294-1779

     The Company may from time to time provide notice to Dr. Holaday that
     notices required under this Agreement shall be provided to a different
     person or to a different address.

24.  Dr. Holaday fully understands, acknowledges and agrees that, (a) in the
     event that he becomes liable for any personal income tax payments or the
     employee's share of FICA and Medicare payments in addition to sums that
     shall be or that have been withheld by the Company and paid to the
     government for such purposes arising out of any portion of the
     consideration provided for under this Agreement or (b) in the event the
     Company becomes liable to any taxing authority in connection with any
     portion of the employee's share of taxes relating to such consideration,
     including, without limitation, for any personal income tax payments, the
     employee's share of FICA and Medicare payroll taxes, interest and penalties
     (collectively, "Employee Taxes"), Dr. Holaday shall pay the

EntreMed, Inc. (signature)                                JWH (signature)
               -----------                                    -----------

                                      -11-
<PAGE>
     taxing authorities such taxes, interest and penalties and shall reimburse
     the Company within thirty (30) days for any Employee Taxes that have been
     paid by the Company as well as all costs and attorneys' fees incurred by
     the Company in connection with such claims from taxing authorities. In
     order to invoke this indemnification provision, the Company must provide
     written notice to Dr. Holaday within sixty (60) days of the receipt by the
     Company of notification from any taxing authority that the Company may be
     liable to that taxing authority for Employee Taxes on any portion of the
     consideration provided to Dr. Holaday pursuant to this Agreement.

25.  Dr. Holaday represents and warrants that he has not heretofore assigned or
     transferred or purported to assign or transfer and shall not assign or
     transfer any claim or obligation herein released to any person or entity.
     Dr. Holaday agrees to indemnify the Company and any third person released
     by Dr. Holaday in Paragraph 9 above, and holds them harmless from and
     against any claim or obligation, including without limitation, for
     attorneys' fees actually paid or incurred, arising out of any such transfer
     or assignment made by Dr. Holaday or any transfer or assignment that is
     claimed to have been made by Dr. Holaday.

26.  In deciding to execute this Agreement, Dr. Holaday has not relied on and
     does not rely on any representation with respect to the subject matter of
     this Agreement or any representation inducing the execution of this
     Agreement except such representations as are expressly set forth in or as
     are incorporated by reference into this Agreement, and Dr. Holaday
     acknowledges that he has relied on his own judgment in entering into this
     Agreement.

27.  This Agreement shall be construed as if both parties participated equally
     in its negotiation and drafting, and both parties agree that any ambiguity
     contained in any provision of this Agreement shall not be construed against
     any party to the Agreement by virtue of that party's role in the
     negotiation or drafting of the Agreement.

28.  Any failure by any part on any occasion to enforce or to require the strict
     adherence to and performance of any term or condition of this Agreement
     shall not constitute a waiver of any such term or condition and shall not
     prevent any party from insisting on the strict adherence to and performance
     of such term or condition on any other or future occasion.

29.  The use of the world "and" is understood to include its conjunctive and
     also its disjunctive meaning, whenever such a disjunctive meaning would
     expand the reach of this Agreement's protections to the Company or to any
     third person released in Paragraphs 9 above. Use of the masculine gender is
     intended to include the feminine. All examples used in this Agreement are
     intended as illustrative and not intended to limit the nature of the
     claims, obligations or persons released. All grammatical forms, including
     the use of singular and plural words, used in this Agreement are to be
     interpreted to provide the maximum protections legally permitted to the
     Company and any third person released in Paragraph 9 above.

EntreMed, Inc. (signature)                                    JWH (signature)
              --------------                                     -------------

                                     - 12 -
<PAGE>

30.  All obligations undertaken by the Company in this Agreement shall be
     binding upon and fully enforceable against its successors and assigns, but
     any such successorship or assignment shall in no way expand or otherwise
     modify the scope of its obligations set forth in this Agreement, and all
     rights of the Company specified in this Agreement shall inure to the
     benefit of its successors and assigns.

31.  The parties expressly acknowledge and agree that nothing in this Agreement
     shall be read to require or allow Dr. Holaday, the Company or any person
     acting for or on the behalf of either to violate any court order, law or
     regulation or to engage in any action or inaction that would constitute or
     otherwise involve a violation of any court order, law or regulation.

32.  This Agreement shall be construed and enforced under Maryland law without
     regard to conflict of law principles, to the extent not governed by federal
     law.

33.  The parties agree that the covenants and provisions of this Agreement are
     severable and that if any covenants, provision or clause or portion thereof
     shall be found unenforceable by any court, only that part will be severed
     from the Agreement, and the remaining covenants, provisions and clauses
     shall continue in force in accordance with the tenor of the Agreement so
     long as the release, settlement and waiver provisions of this Agreement
     that remain enforceable are acceptable to the Company.

34.  DR. HOLADAY EXPRESSLY ACKNOWLEDGES AND AGREES THAT HE HAS READ THIS
     AGREEMENT IN ITS ENTIRETY AND THAT HE UNDERSTANDS AND AGREES TO ITS TERMS;

     (a)  DR. HOLADAY HEREBY IS ADVISED TO CONSULT WITH AN ATTORNEY REGARDING
          ANY POTENTIAL CLAIM OF AGE DISCRIMINATION UNDER THE ADEA AS WELL AS
          THE TERMS OF THIS AGREEMENT BEFORE EXECUTING THIS AGREEMENT, HE
          ACKNOWLEDGES THAT HE HAS BEEN SO ADVISED BY THE COMPANY TO CONSULT
          WITH AN ATTORNEY BEFORE SIGNING THIS AGREEMENT, AND HE AGREES THAT
          THIS PARAGRAPH CONSTITUTES SUCH ADVICE IN WRITING; DR. HOLADAY ASSURES
          THE COMPANY THAT HE HAS OBTAINED LEGAL COUNSEL REGARDING THESE
          SUBJECTS FROM STEPHEN FELDHAUS, ESQUIRE, AND AGREES THAT HE IS
          PERSONALLY RESPONSIBLE FOR THE PAYMENT OF ALL FEES AND EXPENSES
          ASSOCIATED WITH OBTAINING ADVICE FROM MR. FELDHAUS AND FROM OTHER
          COUNSEL WITH WHOM DR. HOLADAY OR MR. FELDHAUS MAY HAVE CONSULTED,
          OTHER THAN THE FIVE THOUSANDS DOLLARS ($5,000) PAID FOR SUCH SERVICES
          BY THE COMPANY; AND DR. HOLADAY HEREBY INDEMNIFIES AND HOLDS THE
          COMPANY HARMLESS FROM ANY CLAIMS FOR ATTORNEYS' FEES AND EXPENSES
          ASSOCIATED WITH SUCH ADVICE;

     (b)  DR. HOLADAY UNDERSTANDS AND AGREES THAT HE IS AND HAS BEEN PERMITTED
          TWENTY-ONE (21) DAYS FROM THE DATE THIS AGREEMENT WAS PRESENTED TO HIM
          TO CONSIDER WHETHER HE WISHES TO ENTER INTO THIS AGREEMENT PROVIDING
          FOR, AMONG OTHER MATTERS, A RELEASE AND WAIVER OF ALL CLAIMS UNDER THE
          ADEA THAT EXIST OR MAY HAVE EXISTED AT THE DATE AND TIME HE EXECUTES
          OR EXECUTED THIS AGREEMENT. DR. HOLADAY UNDERSTANDS AND AGREES THAT
          EVEN UPON (I) DECIDING

EntreMed, Inc. (signature)            -13-                       JWH (signature)
               -----------                                           -----------
<PAGE>
          TO ENTER INTO THIS AGREEMENT, (II) SIGNING THIS AGREEMENT ON OR BEFORE
          SUCH TWENTY-FIRST (21ST) DAY AFTER SUCH PRESENTATION AND (III)
          PROVIDING IT TO THE COMPANY THROUGH ANN MARGARET POINTER, ESQUIRE,
          FISHER & PHILLIPS LLP, 1500 RESURGENS PLAZA, 945 EAST PACES FERRY
          ROAD, ATLANTA, GEORGIA 30326, TELEPHONE (404) 240-4223, TELEFAX (404)
          240-4249, HE MAY REVOKE THIS AGREEMENT BY PROVIDING SUCH REVOCATION IN
          WRITING BY PERSONAL DELIVERY OR VIA TELEFAX TO MS. POINTER, PROVIDED
          SUCH REVOCATION IS ACTUALLY DELIVERED TO MS. POINTER PERSONALLY AND
          RECEIVED BY HER BY TWELVE O'CLOCK NOON E.S.T. OF THE EIGHTH (8TH) DAY
          (OR NEXT BUSINESS DAY THEREAFTER) AFTER THE DATE HE SIGNS THIS
          AGREEMENT. DR. HOLADAY UNDERSTANDS AND AGREES THAT ANY CHANGES TO THE
          TERMS OF THIS AGREEMENT, WHETHER MATERIAL OR IMMATERIAL, THAT MAY HAVE
          BEEN MADE AFTER THE DATE A PROPOSED AGREEMENT HAS BEEN PRESENTED TO
          HIM BY THE COMPANY SHALL NOT RESTART THE TWENTY-ONE (21) DAY PERIOD
          DURING WHICH HE MAY CONSIDER WHETHER HE WISHES TO ENTER INTO THIS
          AGREEMENT. THIS AGREEMENT SHALL NOT BECOME EFFECTIVE AND ENFORCEABLE
          UNTIL (I) DR. HOLADAY HAS EXECUTED THIS AGREEMENT AND HAS PROVIDED A
          SIGNED ORIGINAL OF THIS AGREEMENT TO THE COMPANY AS PROVIDED IN THIS
          PARAGRAPH AND (II) THE REVOCATION PERIOD HAS EXPIRED WITHOUT
          REVOCATION OF THIS AGREEMENT BY THE EIGHTH (8TH) DAY AFTER EXECUTION
          OF THE AGREEMENT BY DR. HOLADAY AS PROVIDED IN THIS PARAGRAPH; AND

     (c)  DR. HOLADAY ASSURES THE COMPANY THAT HE HAS ENTERED THIS AGREEMENT OF
          HIS OWN FREE WILL, KNOWINGLY AND VOLUNTARILY, WITHOUT DURESS OR
          RESERVATION OF ANY KIND, AND AFTER HAVING GIVEN THE MATTER FULL AND
          CAREFUL CONSIDERATION, AND DR. HOLADAY RECOGNIZES AND AGREES THAT HE
          HAS RECEIVED CONSIDERATION FOR THE ENTRY INTO THIS AGREEMENT THAT IS
          IN ADDITION TO RIGHTS AND BENEFITS THAT HE IS ALREADY ENTITLED TO
          RECEIVE FROM THE COMPANY.

35.  DR. HOLADAY ASSURES THE COMPANY THAT HE HAS READ THIS NOTICE CAREFULLY AND
     HAS TAKEN NOTICE THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL CLAIMS,
     WHETHER KNOWN OR UNKNOWN, THAT DR. HOLADAY MAY HAVE IN CONNECTION WITH HIS
     EMPLOYMENT WITH THE COMPANY UP TO AND INCLUDING THE DATE AND TIME OF HIS
     EXECUTION OF THIS AGREEMENT.

WHEREFORE, having been presented a copy of this Agreement as a proposal for my
consideration on January 23, 2003, having fully read this Agreement and now
agreeing to all of its terms and provisions, I, John W. Holaday, Ph.D., execute
this Agreement on this 29 January, 2003, at 2:00 p.m. E.S.T.

                                                   /s/ John W. Holaday
                                                   _____________________________
                                                   John W. Holaday, Ph.D.

EntreMed, Inc. (signature)            -14-                       JWH (signature)
               -----------                                           -----------
<PAGE>
WHEREFORE, having read this Agreement and now agreeing to all of its terms and
provisions, EntreMed, Inc., executes this Agreement on this January 31st, 2003,
at 4:50 p.m. E.S.T.

                                        ENTREMED, INC.

                                        /s/ Wendell M. Starke
                                        ---------------------------------------
                                        By: Wendell M. Starke, Vice Chairman of
                                        the Board of Directors of EntreMed, Inc.

                                        Originally executed on January 29, 2003
                                        at 6:30 p.m. E.S.T. and re-executed
                                        January 31st at 4:50 p.m. E.S.T. as
                                        indicated above.

EntreMed, Inc. (signature)            -15-                       JWH (signature)
               -----------                                           -----------
<PAGE>

                                   SCHEDULE A

EntreMed, Inc.
JOHN HOLADAY
JANUARY 23, 2003

Modify option grants to accelerate vesting and convert all to non-qualified
options. All listed options include the right to exercise options for a period
of 10 years from date of grant.

<Table>
<Caption>
                                                                              EXERCISE
GRANT DATE       EXPIRATION DATE       OPTIONS       VESTING      TYPE         PRICE
----------       ---------------       -------       -------      ----        --------
<S>              <C>                 <C>            <C>           <C>         <C>
12/31/1993            12/31/2003         3,334       Previously    NQ            $6.000
12/31/1994            12/30/2004         3,334       Previously    NQ            $6.375
 11/2/1995             11/1/2005       266,667       Previously    NQ            $6.375
12/31/1995            12/30/2005         3,334       Previously    NQ           $12.000
12/23/1996            12/23/2006        28,568       Previously    I            $14.000
12/23/1996            12/23/2006        71,432       Previously    NQ           $14.000
12/31/1996            12/31/2006         5,000       Previously    NQ           $16.250
  7/1/1997              7/1/2007        10,000       Previously    NQ           $12.000
11/20/1997            11/20/2007       250,000       Previously    NQ           $10.000
 6/26/1998             6/26/2008         5,000       Previously    NQ           $31.938
 2/25/1999             2/25/2009        16,107       Previously    I            $18.625
 2/25/1999             2/25/2009        33,893       Previously    NQ           $18.625
 6/24/1999             6/24/2009        10,000       Previously    NQ           $21.500
 6/24/1999             6/24/2009        37,500       Previously    NQ           $21.500
 6/24/1999             6/24/2009        12,500        6/24/2002    NQ           $21.500
  1/1/2000              1/1/2010         3,902         1/1/2003    I            $25.625
  1/1/2000              1/1/2010        60,000       Previously    I            $25.625
  1/1/2000              1/1/2010        16,098         1/1/2003    NQ           $25.625
 6/22/2000             6/22/2010        30,000       Previously    NQ           $29.125
11/30/2000            11/30/2010        20,000       Previously    NQ           $17.563
11/30/2000            11/30/2010        10,000       11/30/2002    NQ           $17.563
11/30/2000            11/30/2010        10,000       11/30/2003    NQ           $17.563
  4/6/2001              4/6/2011        10,000       Previously    NQ           $14.125
  4/6/2001              4/6/2011        10,000         4/6/2002    NQ           $14.125
  4/6/2001              4/6/2011        10,000         4/6/2003    NQ           $14.125
  4/6/2001              4/6/2011         2,921         4/6/2004    NQ           $14.125
  4/6/2001              4/6/2011         7,079         4/6/2004    I            $14.125
 8/21/2001             8/21/2011        10,250       Previously    NQ           $11.990
 8/21/2001             8/21/2011        10,250        8/21/2002    NQ           $11.990
 8/21/2001             8/21/2011        10,250        8/21/2003    NQ           $11.990
 8/21/2001             8/21/2011        10,250        8/21/2004    NQ           $11.990
 10/1/2001             10/1/2011        37,499       Previously    NQ            $8.970
 10/1/2001             10/1/2011        37,500        10/1/2002    NQ            $8.970
 10/1/2001             10/1/2011        37,499        10/1/2003    NQ            $8.970
 10/1/2001             10/1/2011        37,500        10/1/2004    NQ            $8.970
 10/1/2001             10/1/2011             1        10/1/2003    I             $8.970
 10/1/2001             10/1/2011             1        10/1/2004    I             $8.970
 10/1/2001             10/1/2011         4,750         7/1/2002    NQ            $8.970
 10/1/2001             10/1/2011         4,750         7/1/2003    NQ            $8.970
 10/1/2001             10/1/2011         4,750         7/1/2004    NQ            $8.970
 10/1/2001             10/1/2011         4,750         7/1/2005    I             $8.970
 2/25/2002             2/25/2012        10,000       Previously    NQ            $6.330
  6/6/2002              6/6/2012        20,000       Previously    NQ            $4.850
 9/25/2002             9/25/2012       125,000       Previously    NQ            $1.090
 9/25/2002             9/25/2012        62,500        9/25/2003    NQ            $1.090
 9/25/2002             9/25/2012        62,500        9/25/2004    NQ            $1.090
                                     ---------
                                     1,436,669
                                     ---------
</Table>

EntreMed, Inc. (signature)            -16-                       JWH (signature)
               -----------                                           -----------
<PAGE>

                                   SCHEDULE B

                              TRANSITION AGREEMENT

               1.   Big paintings in Board Room and Lobby
               2.   Small painting Board Room
               3.   Small lithograph above green chair
               4.   Block print on Bathroom Wall
               5.   Various paintings in Dr. Holaday's office
               6.   Two Glass artworks in Dr. Holaday's office
               7.   Indian vase in entrance hall near Benjamin's office
               8.   Fathiya Baabde's sculpture in old office
               9.   Lamps in Dr. Holaday's office
               10.  Green chair and ottoman in Dr. Holaday's old office
               11.  Big plant pot and stand in Dr. Holaday's old office
               12.  Glass tables in Dr. Holaday's office
               13.  Coat rack
               14.  Chest under the desk in old office
               15.  Artificial flowers and pot in old office
               16.  Misc. keepsakes on shelves and drawers in offices

EntreMed, Inc. (signature)            -17-                       JWH (signature)
               -----------                                           -----------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]